News and Media – Amarin Corp

About Amarin

Our Science

Our Partners

Investor Relations

News & Media

Highlighting Our Actions for Cardiovascular Care

Amarin in the Media Spotlight

Year

Items Per Page

Date:

April 29, 2026

Title:

Amarin Reports 2026 First Quarter Financial Results

Format:

Date:

April 15, 2026

Title:

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29...

Format:

Date:

April 8, 2026

Title:

American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Comp...

Format:

Date:

March 18, 2026

Title:

Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular...

Format:

Date:

March 16, 2026

Title:

New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the...

Format:

Date:

March 2, 2026

Title:

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT...

Format:

Date:

February 25, 2026

Title:

Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

Format:

Date:

February 23, 2026

Title:

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available...

Format:

Date:

February 11, 2026

Title:

Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference C...

Format:

Date:

January 9, 2026

Title:

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Compa...

Format:

...

›

Media Contact form

If you’re a journalist or media professional, please feel free to get in touch with our media team by clicking the link below.

MEDIA TOOLKIT

Amarin Logo

Amarin Imagery

Amarin Leadership Team

About Amarin

A committed player in cardiovascular care

Amarin Corporation is committed to stopping cardiovascular disease from being a leading cause of death. Find out more about our vision and how we lead the way to better care for those with cardiovascular disease.

Investor Relations

Our investment in cardiovascular health

Keeping our investors informed about our latest news. Click here for our investor presentations, events and financial results.

Our Science

Passionate about cardiovascular science and health

Learn more about the worlds leading cause of death, CVD and the proven science underpinning our product.

Our Partners

Interested in partnering with Amarin?

We work with leading commercial organizations around the world to bring our product to as many patients as possible. Click here for more information.

Disclaimer

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

ALL-NP-00017 1/23

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT names and logos are trademarks of Amarin Pharmaceuticals Ireland Limited. | ALL-NP-00014 1/23

Get In Touch

Whether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:

Follow Amarin on our social channels for the latest company news, product campaigns and industry updates:

This website is intended for global audiences.